Evidence map›Paper›PMID 34697299›Full record

ArticleTranslational psychiatry2021

Multiple alterations in glutamatergic transmission and dopamine D2 receptor splicing in induced pluripotent stem cell-derived neurons from patients with familial schizophrenia.

Kana Yamamoto, Toshihiko Kuriu, Kensuke Matsumura, Kazuki Nagayasu, Yoshinori Tsurusaki, Noriko Miyake, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Mikiya Fujiwara and 16 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 1 country.

Kana Yamamoto *Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Toshihiko Kuriu *Osaka Medical and Pharmaceutical University, Research and Development Center, Osaka, 569-8686, Japan.ORCID 0000-0001-9125-891X
Kensuke MatsumuraLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Kazuki NagayasuLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Yoshinori TsurusakiDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Kanagawa, 236-0004, Japan.
Noriko MiyakeDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Kanagawa, 236-0004, Japan.
Hidenaga YamamoriDepartment of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, 187-8553, Japan.
Yuka YasudaDepartment of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, 187-8553, Japan.
Michiko FujimotoDepartment of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, 187-8553, Japan.
Mikiya FujiwaraLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Masayuki BabaLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Kohei KitagawaLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Tomoya TakemotoLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Nanaka Gotoda-NishimuraLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Tomohiro TakadaLaboratory of Molecular Biology, Department of Bioscience, Graduate School of Life Sciences, Tokyo University of Agriculture, Tokyo, 156-8502, Japan.
Kaoru SeirikiLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Atsuko Hayata-TakanoLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
Atsushi KasaiLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.ORCID 0000-0002-1612-3078
Yukio AgoDepartment of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami‑ku, Hiroshima, 734‑8553, Japan.ORCID 0000-0001-7562-4000
Satoshi KidaGraduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.ORCID 0000-0002-8038-9583
Kazuhiro TakumaMolecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University, and University of Fukui, Osaka, 565-0871, Japan.
Fumihito OnoDepartment of Physiology, Osaka Medical and Pharmaceutical University, Osaka, 569-8686, Japan.ORCID 0000-0001-7532-5262
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Kanagawa, 236-0004, Japan.ORCID 0000-0001-9846-6500
Ryota HashimotoDepartment of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, 187-8553, Japan. ryotahashimoto55@ncnp.go.jp.
Hitoshi HashimotoLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan. hasimoto@phs.osaka-u.ac.jp.ORCID 0000-0001-6548-4016
Takanobu NakazawaLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan. tn207427@nodai.ac.jp.ORCID 0000-0003-4863-1277
The University of Osaka · JPNational Center of Neurology and Psychiatry · JPKanazawa University · JPOsaka University of Pharmaceutical Sciences · JPTokyo University of Agriculture · JPYokohama City University · JPHiroshima University · JPKyoto University · JPNational Center for Global Health and Medicine · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing body of evidence suggests that impaired synapse development and function are associated with schizophrenia; however, the underlying molecular pathophysiological mechanism of the disease remains largely unclear. We conducted a family-based study combined with molecular and cellular analysis using induced pluripotent stem cell (iPSC) technology. We generated iPSCs from patients with familial schizophrenia, differentiated these cells into neurons, and investigated the molecular and cellular phenotypes of the patient's neurons. We identified multiple altered synaptic functions, including increased glutamatergic synaptic transmission, higher synaptic density, and altered splicing of dopamine D2 receptor mRNA in iPSC-derived neurons from patients. We also identified patients' specific genetic mutations using whole-exome sequencing. Our findings support the notion that altered synaptic function may underlie the molecular and cellular pathophysiology of schizophrenia, and that multiple genetic factors cooperatively contribute to the development of schizophrenia.

Indexed as

Induced Pluripotent Stem CellsSchizophreniaCell DifferentiationHumansNeuronsReceptors, Dopamine D2Receptors, Dopamine D2

Identifiers

PMID34697299
PMCPMC8547217
OpenAlexW3208678303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.